ATP Assays Market Size 2023: Business Strategies, Current Insights, Regional Developments and Demand by 2028

ATP Assays Market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $0.5 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. The ATP Assays market is mainly driven by factors such as growing drug discovery & development studies, growing penetration of CROs, increasing demand for cell-based assays in research, growing investments by pharmaceutical and biotechnology companies are some of the key factors driving the market for ATP assays.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223438780&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

The consumables & accessories segment is accounted for largest share of the market during the forecast period

On the basis of product, The ATP assays market comprises consumables & accessories as well as instruments, with the consumables & accessories segment holding a significant portion. This dominance can be attributed to the the growing demand for tumor testing and cell proliferation (specifically in cancer) driven by an upsurge in chronic diseases, and the frequent procurement of consumables by pharmaceutical and biotechnology firms.

The contamination testing segment accounted for the largest share of the market during the forecast period.

On the basis of application, The ATP assays market is bifurcated into contamination testing, disease testing, and drug delivery & development segments. The significant portion of the contamination testing segment is due to various factors such as the surge in drug discovery activities following the COVID-19 pandemic, and the necessity for cleaning and disinfecting environmental surfaces in hospitals.

The pharmaceutical & biotechnology segment accounted for the largest share of the market in 2022

On the basis of end users, The ATP assays market is categorized into pharmaceutical & biotechnology companies, the food & beverage industry, hospitals & diagnostic laboratories, and academic & research institutes. The dominance of this segment can be attributed to several key factors. These include the presence of a large number of pharmaceutical players who are making substantial investments in this market, the growing regulatory approvals for cell culture-based vaccines that necessitate the use of ATP assays in contamination testing, the expansion of commercial activities by various pharmaceutical companies, the rising demand for cell and gene therapies to address chronic diseases, and significant research and development efforts in the pharmaceutical & biopharmaceutical sector.

APAC to witness the highest growth during the forecast period.

North America accounted for the largest share the ATP assays market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the availability of government and private funding for life science research, growing penetration of CROs, comprehensive drug development regulations, and the presence of major players in the ATP assays market in this region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=223438780&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Key Market Players:

The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), Neogen Corporation (US), 3M (US), Danaher Corporation (US), PromoCell GmbH (Germany), Geno Technology, Inc. (US), Abnova Corporation (Taiwan), AAT Bioquest Inc. (US), BioThema AB (Sweden), Elabscience Biotechnology Inc. (US), MBL International Corporation (US), Biotium (US), Creative Bioarray (US), Canvax Biotech S.L. (Spain), Ruhof Corporation (US), Charm Sciences, Inc. (US), Bio Shield Tech, LLC (US), Cayman Chemical (US), and Cell Signaling Technology,Inc. (US).

Recent Developments:

In January 2022, Agilent Technologies launched Seahorse XF Pro Analyzer, enabling operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function.

In May 2021, Neogen Corporation launched AccuPoint Advanced NG. It remains the only sanitation monitoring system in the market to utilize a flat tip sampler for maximized recovery of ATP and feature RFID technology for streamlined testing processes.

In October 2021, Abcam has doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam's growth journey in the US and will further enable its commitment to support the research and biopharma sector globally.

In May 2020, Thermo Fisher launched the Orbitrap 240 Mass Spectrometer. It is designed to give proteomics, metabolomics, and biopharmaceutical characterization to small molecules, which aid in research and high-throughput analyses. The new system helps drive discovery and identification with increased accuracy for confident scale-up along with operational simplicity and speed.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=223438780&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/atp-assay-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/atp-assay.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.